Berenson JR - Search Results

1

Safety of prolonged therapy with bortezomib in relapsed or refractory multiple myeloma.

Berenson JR, Jagannath S, Barlogie B, Siegel DT, Alexanian R, Richardson PG, Irwin D, Alsina M, Rajkumar SV, Srkalovic G, Singhal S, Limentani S, Niesvizky R, Esseltine DL, Trehu E, Schenkein DP, Anderson K. Berenson JR, et al. Cancer. 2005 Nov 15;104(10):2141-8. doi: 10.1002/cncr.21427. Cancer. 2005. PMID: 16206291 Free article. Clinical Trial.

2

Bisphosphonates in multiple myeloma.

Berenson JR. Berenson JR. Cancer. 1997 Oct 15;80(8 Suppl):1661-7. doi: 10.1002/(sici)1097-0142(19971015)80:8+<1661::aid-cncr16>3.3.co;2-t. Cancer. 1997. PMID: 9362433 Review.

3

Multiple myeloma and chronic lymphocytic leukemia.

Rosen L, Vescio R, Berenson JR. Rosen L, et al. Among authors: berenson jr. Curr Opin Hematol. 1995 Jul;2(4):275-82. doi: 10.1097/00062752-199502040-00007. Curr Opin Hematol. 1995. PMID: 9372008 Review.

4

BCL-X expression in multiple myeloma: possible indicator of chemoresistance.

Tu Y, Renner S, Xu F, Fleishman A, Taylor J, Weisz J, Vescio R, Rettig M, Berenson J, Krajewski S, Reed JC, Lichtenstein A. Tu Y, et al. Cancer Res. 1998 Jan 15;58(2):256-62. Cancer Res. 1998. PMID: 9443402

5

Zoledronic acid reduces skeletal-related events in patients with osteolytic metastases.

Berenson JR, Rosen LS, Howell A, Porter L, Coleman RE, Morley W, Dreicer R, Kuross SA, Lipton A, Seaman JJ. Berenson JR, et al. Cancer. 2001 Apr 1;91(7):1191-200. doi: 10.1002/1097-0142(20010401)91:7<1191::aid-cncr1119>3.0.co;2-0. Cancer. 2001. PMID: 11283917 Clinical Trial.

6

Maintenance therapy with alternate-day prednisone improves survival in multiple myeloma patients.

Berenson JR, Crowley JJ, Grogan TM, Zangmeister J, Briggs AD, Mills GM, Barlogie B, Salmon SE. Berenson JR, et al. Blood. 2002 May 1;99(9):3163-8. doi: 10.1182/blood.v99.9.3163. Blood. 2002. PMID: 11964279 Free article. Clinical Trial.

7

The role of cytotoxic therapy with hematopoietic stem cell transplantation in the therapy of multiple myeloma: an evidence-based review.

Hahn T, Wingard JR, Anderson KC, Bensinger WI, Berenson JR, Brozeit G, Carver JR, Kyle RA, McCarthy PL Jr. Hahn T, et al. Among authors: berenson jr. Biol Blood Marrow Transplant. 2003 Jan;9(1):4-37. doi: 10.1053/bbmt.2003.50002. Biol Blood Marrow Transplant. 2003. PMID: 12533739 Free article. Review.

8

A phase 2 study of bortezomib in relapsed, refractory myeloma.

Richardson PG, Barlogie B, Berenson J, Singhal S, Jagannath S, Irwin D, Rajkumar SV, Srkalovic G, Alsina M, Alexanian R, Siegel D, Orlowski RZ, Kuter D, Limentani SA, Lee S, Hideshima T, Esseltine DL, Kauffman M, Adams J, Schenkein DP, Anderson KC. Richardson PG, et al. N Engl J Med. 2003 Jun 26;348(26):2609-17. doi: 10.1056/NEJMoa030288. N Engl J Med. 2003. PMID: 12826635 Free article. Clinical Trial.

9

A prospective, open-label safety and efficacy study of combination treatment with bortezomib (PS-341, velcade and melphalan in patients with relapsed or refractory multiple myeloma.

Yang HH, Vescio R, Schenkein D, Berenson JR. Yang HH, et al. Among authors: berenson jr. Clin Lymphoma. 2003 Sep;4(2):119-22. doi: 10.3816/clm.2003.n.022. Clin Lymphoma. 2003. PMID: 14556685 Clinical Trial. No abstract available.

10

Overcoming drug resistance in multiple myeloma: the emergence of therapeutic approaches to induce apoptosis.

Yang HH, Ma MH, Vescio RA, Berenson JR. Yang HH, et al. Among authors: berenson jr. J Clin Oncol. 2003 Nov 15;21(22):4239-47. doi: 10.1200/JCO.2003.06.001. J Clin Oncol. 2003. PMID: 14615454 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

287 results

Search Page

Filters